Autopsy report · NCT00437294

Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

“Lack of efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years before it stopped.
• 86 participants enrolled.
• Results were posted on the registry 11 years 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Conditions

Breast Cancer

Interventions

enzastaurin; placebo; capecitabine

Participants

86

Sites

20

Countries

Argentina, Australia, France, Mexico, South Africa

Trials that died the same way

• Cross Linking for Treatment of Corneal Infection
  “insufficient efficacy” (91% match in meaning)
• Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
  “lack of efficacy and lack of funding” (85% match in meaning)
• Influence of Esmolol on a Closed-Loop Anesthesia System
  “lack of effectiveness” (81% match in meaning)
• Efficacy of the Infusion of Donor Plasma in COVID-19 Infection
  “Lack of efficacy of treatment tested” (77% match in meaning)
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
  “Lack of efficacy. Stopped at first interim evaluation point” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.